Henry Schein vs Boston Scientific
Side-by-side comparison of AI visibility scores, market position, and capabilities
World's largest dental/medical distributor; recovered from 2023 ALPHV ransomware attack; $12.4B 2024 revenue; digital dentistry platform driving recurring tech revenue.
About
Henry Schein is the world's largest provider of health care solutions to office-based dental and medical practitioners, founded in 1932 by Henry Schein in Queens, New York, and headquartered in Melville, New York. The company trades on Nasdaq (HSIC) and generated approximately $12.4 billion in net sales in 2024, serving over one million healthcare practitioners across more than 30 countries. Henry Schein operates through two segments: Health Care Distribution, supplying dental and medical consumables, equipment, and technology; and Technology and Value-Added Services, offering practice management software and digital dentistry solutions under brands like Dentrix, Dexis, and Axium.
Marlborough MA cardiac devices leader (NYSE: BSX) $16.7B FY2024 revenue (+18%); Farapulse PFA ablation fastest-growing EP device, WATCHMAN FLX 70%+ LAAC share, competing with Abbott and Medtronic.
About
Boston Scientific Corporation is a Marlborough, Massachusetts-based global medical device company — publicly traded on the New York Stock Exchange (NYSE: BSX) as an S&P 500 Health Care component — developing and commercializing medical devices for minimally invasive diagnosis and treatment of cardiovascular disease, cardiac rhythm management, electrophysiology, urology, endoscopy, and neuromodulation through approximately 48,000 employees in 130 countries. In fiscal year 2024, Boston Scientific reported revenues of $16.7 billion (+18% year-over-year) — driven by the Farapulse pulsed field ablation (PFA) system for atrial fibrillation treatment, WATCHMAN FLX left atrial appendage closure (LAAC) device, and Rhythmia Ultra high-density cardiac mapping — making Boston Scientific the fastest-growing large-cap medical device company and one of the strongest organic growth stories in healthcare. CEO Mike Mahoney has executed acquisitions and organic R&D investment to build a diverse cardiovascular and electrophysiology portfolio: the 2023 acquisition of Apollo Endosurgery ($615 million, flexible endoscopic stapling for minimally invasive procedures) and the 2022 acquisition of Lumenis (surgical laser systems) expanded Boston Scientific beyond the cardiac core. Boston Scientific's strongest 2024 growth driver — Farapulse (pulsed field ablation) — achieved rapid adoption as a new standard-of-care in atrial fibrillation ablation by delivering shorter procedure times (2-hour PFA versus 4-hour radiofrequency ablation) and improved safety profile compared to traditional thermal ablation methods.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.